DNLI Q3 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$123M

Net Income

-$107M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$63M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$136M

Stockholders' Equity

$1.3B

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$1M	-100.0%
Gross Profit	$0	$1M	-100.0%
Operating Income	-$123M	-$114M	-8.3%
Net Income	-$107M	-$99M	-7.9%